Cargando…

Protective effects of oral anticoagulants on cerebrovascular diseases and cognitive impairment in patients with atrial fibrillation: protocol for a multicentre, prospective, observational, longitudinal cohort study (Strawberry study)

INTRODUCTION: Non-valvular atrial fibrillation (NVAF) is known as a robust risk factor for stroke. Recent reports have suggested a risk of dementia with NVAF, but much remains unknown regarding the relationship between this mechanism and the potential protective effects of novel anticoagulants (dire...

Descripción completa

Detalles Bibliográficos
Autores principales: Saji, Naoki, Sakurai, Takashi, Ito, Kengo, Tomimoto, Hidekazu, Kitagawa, Kazuo, Miwa, Kaori, Tanaka, Yuji, Kozaki, Koichi, Kario, Kazuomi, Eto, Masato, Suzuki, Keisuke, Shimizu, Atsuya, Niida, Shumpei, Hirakawa, Akihiro, Toba, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254414/
https://www.ncbi.nlm.nih.gov/pubmed/30478106
http://dx.doi.org/10.1136/bmjopen-2018-021759
_version_ 1783373710262009856
author Saji, Naoki
Sakurai, Takashi
Ito, Kengo
Tomimoto, Hidekazu
Kitagawa, Kazuo
Miwa, Kaori
Tanaka, Yuji
Kozaki, Koichi
Kario, Kazuomi
Eto, Masato
Suzuki, Keisuke
Shimizu, Atsuya
Niida, Shumpei
Hirakawa, Akihiro
Toba, Kenji
author_facet Saji, Naoki
Sakurai, Takashi
Ito, Kengo
Tomimoto, Hidekazu
Kitagawa, Kazuo
Miwa, Kaori
Tanaka, Yuji
Kozaki, Koichi
Kario, Kazuomi
Eto, Masato
Suzuki, Keisuke
Shimizu, Atsuya
Niida, Shumpei
Hirakawa, Akihiro
Toba, Kenji
author_sort Saji, Naoki
collection PubMed
description INTRODUCTION: Non-valvular atrial fibrillation (NVAF) is known as a robust risk factor for stroke. Recent reports have suggested a risk of dementia with NVAF, but much remains unknown regarding the relationship between this mechanism and the potential protective effects of novel anticoagulants (direct oral anticoagulants (DOACs), or non-vitamin K oral anticoagulants). METHODS AND ANALYSIS: This study, the strategy to obtain warfarin or DOAC’s benefit by evaluating registry, is an investigator-initiated, multicentre, prospective, observational, longitudinal cohort study comparing the effects of warfarin therapy and DOACs on cerebrovascular diseases and cognitive impairment over an estimated duration of 36 months. Once a year for 3 years, the activities of daily living and cognitive functioning of non-demented patients with NVAF will be assessed. Demographics, risk factors, laboratory investigations, lifestyle, social background and brain MRI will be assessed. ETHICS AND DISSEMINATION: This protocol has been approved by the ethics committee of the National Center for Geriatrics and Gerontology (No. 1017) and complies with the Declaration of Helsinki. Informed consent will be obtained before study enrolment and only coded data will be stored in a secured database. The results will be published in peer-reviewed journals and presented at scientific meetings to ensure the applicability of the findings in clinical practice. TRIAL REGISTRATION NUMBER: UMIN000025721.
format Online
Article
Text
id pubmed-6254414
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-62544142018-12-11 Protective effects of oral anticoagulants on cerebrovascular diseases and cognitive impairment in patients with atrial fibrillation: protocol for a multicentre, prospective, observational, longitudinal cohort study (Strawberry study) Saji, Naoki Sakurai, Takashi Ito, Kengo Tomimoto, Hidekazu Kitagawa, Kazuo Miwa, Kaori Tanaka, Yuji Kozaki, Koichi Kario, Kazuomi Eto, Masato Suzuki, Keisuke Shimizu, Atsuya Niida, Shumpei Hirakawa, Akihiro Toba, Kenji BMJ Open Neurology INTRODUCTION: Non-valvular atrial fibrillation (NVAF) is known as a robust risk factor for stroke. Recent reports have suggested a risk of dementia with NVAF, but much remains unknown regarding the relationship between this mechanism and the potential protective effects of novel anticoagulants (direct oral anticoagulants (DOACs), or non-vitamin K oral anticoagulants). METHODS AND ANALYSIS: This study, the strategy to obtain warfarin or DOAC’s benefit by evaluating registry, is an investigator-initiated, multicentre, prospective, observational, longitudinal cohort study comparing the effects of warfarin therapy and DOACs on cerebrovascular diseases and cognitive impairment over an estimated duration of 36 months. Once a year for 3 years, the activities of daily living and cognitive functioning of non-demented patients with NVAF will be assessed. Demographics, risk factors, laboratory investigations, lifestyle, social background and brain MRI will be assessed. ETHICS AND DISSEMINATION: This protocol has been approved by the ethics committee of the National Center for Geriatrics and Gerontology (No. 1017) and complies with the Declaration of Helsinki. Informed consent will be obtained before study enrolment and only coded data will be stored in a secured database. The results will be published in peer-reviewed journals and presented at scientific meetings to ensure the applicability of the findings in clinical practice. TRIAL REGISTRATION NUMBER: UMIN000025721. BMJ Publishing Group 2018-11-25 /pmc/articles/PMC6254414/ /pubmed/30478106 http://dx.doi.org/10.1136/bmjopen-2018-021759 Text en © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Neurology
Saji, Naoki
Sakurai, Takashi
Ito, Kengo
Tomimoto, Hidekazu
Kitagawa, Kazuo
Miwa, Kaori
Tanaka, Yuji
Kozaki, Koichi
Kario, Kazuomi
Eto, Masato
Suzuki, Keisuke
Shimizu, Atsuya
Niida, Shumpei
Hirakawa, Akihiro
Toba, Kenji
Protective effects of oral anticoagulants on cerebrovascular diseases and cognitive impairment in patients with atrial fibrillation: protocol for a multicentre, prospective, observational, longitudinal cohort study (Strawberry study)
title Protective effects of oral anticoagulants on cerebrovascular diseases and cognitive impairment in patients with atrial fibrillation: protocol for a multicentre, prospective, observational, longitudinal cohort study (Strawberry study)
title_full Protective effects of oral anticoagulants on cerebrovascular diseases and cognitive impairment in patients with atrial fibrillation: protocol for a multicentre, prospective, observational, longitudinal cohort study (Strawberry study)
title_fullStr Protective effects of oral anticoagulants on cerebrovascular diseases and cognitive impairment in patients with atrial fibrillation: protocol for a multicentre, prospective, observational, longitudinal cohort study (Strawberry study)
title_full_unstemmed Protective effects of oral anticoagulants on cerebrovascular diseases and cognitive impairment in patients with atrial fibrillation: protocol for a multicentre, prospective, observational, longitudinal cohort study (Strawberry study)
title_short Protective effects of oral anticoagulants on cerebrovascular diseases and cognitive impairment in patients with atrial fibrillation: protocol for a multicentre, prospective, observational, longitudinal cohort study (Strawberry study)
title_sort protective effects of oral anticoagulants on cerebrovascular diseases and cognitive impairment in patients with atrial fibrillation: protocol for a multicentre, prospective, observational, longitudinal cohort study (strawberry study)
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254414/
https://www.ncbi.nlm.nih.gov/pubmed/30478106
http://dx.doi.org/10.1136/bmjopen-2018-021759
work_keys_str_mv AT sajinaoki protectiveeffectsoforalanticoagulantsoncerebrovasculardiseasesandcognitiveimpairmentinpatientswithatrialfibrillationprotocolforamulticentreprospectiveobservationallongitudinalcohortstudystrawberrystudy
AT sakuraitakashi protectiveeffectsoforalanticoagulantsoncerebrovasculardiseasesandcognitiveimpairmentinpatientswithatrialfibrillationprotocolforamulticentreprospectiveobservationallongitudinalcohortstudystrawberrystudy
AT itokengo protectiveeffectsoforalanticoagulantsoncerebrovasculardiseasesandcognitiveimpairmentinpatientswithatrialfibrillationprotocolforamulticentreprospectiveobservationallongitudinalcohortstudystrawberrystudy
AT tomimotohidekazu protectiveeffectsoforalanticoagulantsoncerebrovasculardiseasesandcognitiveimpairmentinpatientswithatrialfibrillationprotocolforamulticentreprospectiveobservationallongitudinalcohortstudystrawberrystudy
AT kitagawakazuo protectiveeffectsoforalanticoagulantsoncerebrovasculardiseasesandcognitiveimpairmentinpatientswithatrialfibrillationprotocolforamulticentreprospectiveobservationallongitudinalcohortstudystrawberrystudy
AT miwakaori protectiveeffectsoforalanticoagulantsoncerebrovasculardiseasesandcognitiveimpairmentinpatientswithatrialfibrillationprotocolforamulticentreprospectiveobservationallongitudinalcohortstudystrawberrystudy
AT tanakayuji protectiveeffectsoforalanticoagulantsoncerebrovasculardiseasesandcognitiveimpairmentinpatientswithatrialfibrillationprotocolforamulticentreprospectiveobservationallongitudinalcohortstudystrawberrystudy
AT kozakikoichi protectiveeffectsoforalanticoagulantsoncerebrovasculardiseasesandcognitiveimpairmentinpatientswithatrialfibrillationprotocolforamulticentreprospectiveobservationallongitudinalcohortstudystrawberrystudy
AT kariokazuomi protectiveeffectsoforalanticoagulantsoncerebrovasculardiseasesandcognitiveimpairmentinpatientswithatrialfibrillationprotocolforamulticentreprospectiveobservationallongitudinalcohortstudystrawberrystudy
AT etomasato protectiveeffectsoforalanticoagulantsoncerebrovasculardiseasesandcognitiveimpairmentinpatientswithatrialfibrillationprotocolforamulticentreprospectiveobservationallongitudinalcohortstudystrawberrystudy
AT suzukikeisuke protectiveeffectsoforalanticoagulantsoncerebrovasculardiseasesandcognitiveimpairmentinpatientswithatrialfibrillationprotocolforamulticentreprospectiveobservationallongitudinalcohortstudystrawberrystudy
AT shimizuatsuya protectiveeffectsoforalanticoagulantsoncerebrovasculardiseasesandcognitiveimpairmentinpatientswithatrialfibrillationprotocolforamulticentreprospectiveobservationallongitudinalcohortstudystrawberrystudy
AT niidashumpei protectiveeffectsoforalanticoagulantsoncerebrovasculardiseasesandcognitiveimpairmentinpatientswithatrialfibrillationprotocolforamulticentreprospectiveobservationallongitudinalcohortstudystrawberrystudy
AT hirakawaakihiro protectiveeffectsoforalanticoagulantsoncerebrovasculardiseasesandcognitiveimpairmentinpatientswithatrialfibrillationprotocolforamulticentreprospectiveobservationallongitudinalcohortstudystrawberrystudy
AT tobakenji protectiveeffectsoforalanticoagulantsoncerebrovasculardiseasesandcognitiveimpairmentinpatientswithatrialfibrillationprotocolforamulticentreprospectiveobservationallongitudinalcohortstudystrawberrystudy